CBER Embarks On “Critical Path”: Pre-Pre-IND Meeting Guidance Requested
Executive Summary
FDA will consider defining the procedures for requesting "pre-pre-IND" meetings, the agency said at a public workshop on facilitating biologics development Oct. 7